VVOS - Vivos Therapeutics, Inc. Stock Price, Fair Value and News

2.46USD-0.11 (-4.28%)Market Closed

Market Summary

USD2.46-0.11

Market Closed

-4.28%

VVOS Stock Price

View Fullscreen

VVOS RSI Chart

VVOS Valuation

Market Cap

6.7M

Price/Earnings (Trailing)

-0.49

Price/Sales (Trailing)

0.49

EV/EBITDA

-0.3

Price/Free Cashflow

-0.53

VVOS Price/Sales (Trailing)

VVOS Profitability

EBT Margin

-129.52%

Return on Equity

-3.3K%

Return on Assets

-126.59%

Free Cashflow Yield

-189.06%

VVOS Fundamentals

VVOS Revenue

Revenue (TTM)

13.8M

Rev. Growth (Yr)

-17.77%

Rev. Growth (Qtr)

-1.61%

VVOS Earnings

Earnings (TTM)

-13.6M

Earnings Growth (Yr)

30.05%

Earnings Growth (Qtr)

-103.49%

Breaking Down VVOS Revenue

Last 7 days

-7.5%

Last 30 days

-45.0%

Last 90 days

-54.4%

Trailing 12 Months

668.8%

How does VVOS drawdown profile look like?

VVOS Financial Health

Current Ratio

0.34

VVOS Investor Care

Buy Backs (1Y)

90.87%

Diluted EPS (TTM)

-9.98

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	16.2M	15.4M	14.5M	13.8M
2022	17.1M	16.8M	16.5M	16.0M
2021	13.3M	14.5M	15.8M	16.9M
2020	11.8M	12.2M	12.6M	13.1M
2019	0	0	0	11.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Vivos Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jun 20, 2023	huntsman ronald kirk	bought	7,420	0.53	14,000	chief executive officer
Jun 16, 2023	huntsman ronald kirk	bought	8,050	0.536667	15,000	chief executive officer
Jun 15, 2023	huntsman ronald kirk	bought	10.5	0.5	21.00	chief executive officer
Jun 14, 2023	huntsman ronald kirk	bought	4,900	0.49	10,000	chief executive officer
Dec 23, 2022	huntsman ronald kirk	bought	10,000	0.5	20,000	chief executive officer
Jun 01, 2022	huntsman ronald kirk	bought	7,320	1.83	4,000	chief executive officer
May 31, 2022	huntsman ronald kirk	bought	16,240	2.03	8,000	chief executive officer
Sep 21, 2021	huntsman ronald kirk	bought	21,550	4.31	5,000	chief executive officer
Aug 17, 2021	huntsman ronald kirk	bought	15,000	3.00	5,000	chief executive officer
May 25, 2021	amman bradford k.	bought	5,290	5.29	1,000	chief financial officer

Which funds bought or sold VVOS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 24, 2024	Newbridge Financial Services Group, Inc.	added	50.58	-6,691	9,419	-%
Apr 23, 2024	Global Retirement Partners, LLC	unchanged	-	-54.00	111	-%
Apr 19, 2024	Cutler Group LLC / CA	sold off	-100	-	-	-%
Mar 11, 2024	VANGUARD GROUP INC	sold off	-100	-118,144	-	-%
Mar 11, 2024	VANGUARD GROUP INC	new	-	131,603	131,603	-%
Feb 14, 2024	Royal Bank of Canada	sold off	-100	-	-	-%
Feb 14, 2024	Royal Bank of Canada	new	-	-	-	-%
Feb 14, 2024	LPL Financial LLC	sold off	-100	-6,816	-	-%
Feb 14, 2024	Schonfeld Strategic Advisors LLC	new	-	623,244	623,244	-%
Feb 14, 2024	GROUP ONE TRADING, L.P.	new	-	4,827	4,827	-%

Are Funds Buying or Selling VVOS?

Are funds buying VVOS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VVOS

No. of Funds

Unveiling Vivos Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	9.99%	175,099	SC 13G
Feb 14, 2024	huntsman ronald kirk	3.2%	69,600	SC 13G/A
Feb 10, 2023	huntsman ronald kirk	6.0%	1,740,000	SC 13G/A
Feb 14, 2022	singh gurdev dave	14.0%	3,219,705	SC 13G/A
Feb 14, 2022	huntsman ronald kirk	7.6%	1,740,000	SC 13G/A

Recent SEC filings of Vivos Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 22, 2024	S-1/A	Initial Public Offering
Apr 09, 2024	S-1	Initial Public Offering
Mar 29, 2024	8-K	Current Report
Mar 28, 2024	10-K	Annual Report
Feb 15, 2024	8-K	Current Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G	Major Ownership Report

Peers (Alternatives to Vivos Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	185.5B	40.1B	-4.14%	-1.72%	32.41	4.62	-8.12%	-17.45%
BDX	66.6B	19.5B	-4.72%	-10.85%	53.01	3.42	4.02%	-22.04%
ALGN	23.3B	3.9B	-2.96%	-12.43%	52.39	6.04	3.42%	23.09%
BAX	20.4B	14.8B	-3.18%	-12.72%	7.69	1.38	2.12%	209.17%
MID-CAP
HSIC	9.4B	12.3B	-0.07%	-10.32%	22.5	0.76	-2.44%	-22.68%
ATR	9.3B	3.5B	-1.98%	21.26%	32.57	2.66	4.97%	18.89%
BIO	8.0B	2.7B	-19.10%	-36.82%	-12.63	3.01	-4.68%	82.43%
XRAY	6.3B	4.0B	-6.58%	-25.82%	-46.81	1.59	1.10%	85.84%
AXNX	3.4B	366.4M	-3.44%	15.93%	-559.62	9.27	33.86%	89.83%
PDCO	2.3B	6.6B	-4.62%	-2.20%	11.94	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-14.98%	-16.46%	-1.88	0.4	7.73%	-1066.14%
ANIK	380.3M	166.7M	0.99%	-2.77%	-4.6	2.28	6.67%	-456.34%
ANGO	231.9M	324.0M	7.22%	-30.16%	-1.21	0.72	-3.19%	-337.41%
APYX	50.2M	52.3M	13.28%	-50.68%	-2.68	0.96	17.61%	19.28%
AEMD	3.9M	3.7M	-14.29%	284.62%	-0.32	1.05	5.77%	8.23%

Vivos Therapeutics, Inc. News

Latest updates

Vivos Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Revenue	-1.6%	3,248,000	3,301,000	3,395,000	3,857,000	3,950,000	4,246,000	4,184,000	3,644,000	4,394,000	4,546,000	4,497,000	3,448,000	3,306,703	3,291,602	3,271,188	3,196,507	-
Gross Profit	2.1%	1,938,000	1,898,000	2,098,000	2,337,000	2,384,000	2,496,000	2,588,000	2,551,000	3,107,000	3,183,000	3,624,000	2,690,000	2,688,189	2,582,418	2,726,342	2,416,051	-
Operating Expenses	15.5%	6,222,500	5,387,000	6,615,000	7,342,000	8,426,000	7,903,000	9,552,000	9,190,000	10,518,500	8,686,000	7,685,000	6,096,000	8,935,922	4,399,633	4,143,670	4,973,775	-
S&GA Expenses	-5.5%	606,000	641,000	590,000	630,000	1,568,500	1,106,000	1,699,000	753,000	1,317,000	1,976,000	1,398,000	860,000	820,270	431,704	502,190	559,836	-
EBITDA Margin	9.1%	-1.25	-1.38	-1.50	-1.43	-1.45	-1.48	-1.46	-1.26	-1.16	-0.71	-0.78	-0.85	-0.86	-0.78	-0.81	-0.84	-0.87
Interest Expenses	-	-	-	-	-	-2,000	-	-	2,000	1,631	9,488	251	5,000	17,218	16,992	18,067	43,723	-
Earnings Before Taxes	-103.5%	-4,259,000	-2,093,000	-	-	-6,088,500	-5,434,000	-6,992,000	-5,331,000	-7,393,000	-5,453,000	-4,043,000	-3,399,000	-	-	-	-	-
EBT Margin	8.9%	-1.30	-1.42	-1.54	-1.47	-1.49	-1.53	-1.50	-1.30	-1.20	-0.76	-0.83	-0.91	-0.92	-0.85	-0.88	-0.91	-0.94
Net Income	-103.5%	-4,259,000	-2,093,000	-5,528,000	-1,703,000	-6,088,500	-5,434,000	-6,992,000	-5,331,000	-7,393,000	-5,453,000	-4,043,000	-3,399,000	-6,249,593	-1,813,168	-1,413,672	-2,580,567	-
Net Income Margin	7.4%	-0.98	-1.06	-1.21	-1.25	-1.49	-1.53	-1.50	-1.30	-1.20	-1.21	-1.07	-0.97	-0.92	-0.85	-0.88	-0.91	-0.94
Free Cashflow	3.0%	-2,865,000	-2,954,000	-3,143,000	-3,739,000	-3,213,000	-5,987,000	-5,104,000	-6,220,000	-4,504,000	-4,454,000	-5,050,000	-4,123,000	-3,713,041	-686,445	-958,400	-442,114	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet														(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2019Q4
Assets	4.0%	10,730	10,317	13,749	17,100	13,720	18,400	24,375	29,556	33,689	41,024	46,156	21,954	25,327	7,552
Current Assets	24.0%	2,461	1,985	5,342	8,713	5,424	9,701	15,513	21,601	27,324	34,031	39,389	16,735	20,394	1,984
Cash Equivalents	61.9%	1,600	988	3,900	7,046	3,519	6,719	12,700	17,828	24,000	28,535	34,198	14,058	18,206	469
Net PPE	0.9%	3,314	3,283	3,267	3,157	3,082	3,044	3,109	2,913	2,825	2,601	2,291	1,058	872	1,140
Goodwill	0%	2,843	2,843	2,843	2,843	2,843	2,843	2,843	2,843	2,843	2,843	2,843	400	2,671	2,671
Liabilities	0.3%	10,300	10,271	11,600	10,107	8,919	8,545	9,536	8,500	8,150	8,555	9,673	7,613	8,410	9,178
Current Liabilities	1.7%	7,289	7,167	8,440	7,975	6,813	5,964	6,694	6,292	7,509	8,195	9,314	7,295	7,841	9,094
LT Debt, Current	-	-	-	-	-	-	-	-	-	1,265	1,265	1,265	1,159	867	3,710
Shareholder's Equity	793.5%	411	46.00	2,106	6,993	4,801	9,855	14,839	21,039	25,539	32,469	36,479	14,340	16,917	-
Retained Earnings	-4.9%	-93,100	-88,792	-86,700	-81,200	-79,468	-73,400	-67,946	-61,000	-55,623	-48,229	-42,776	-38,733	-35,335	-23,277
Additional Paid-In Capital	5.2%	93,462	88,838	88,802	88,161	84,269	83,233	82,783	81,991	81,162	80,697	79,258	53,073	52,250	20,334
Shares Outstanding	-	1,834	-	29,929	29,929	-	23,012	21,233	-	-	20,826,499	19,482,056	-	18,209	12,444
Float	-	-	-	15,300	-	-	-	23,200	-	-	-	88,300	-	73,000	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Cashflow From Operations	3.6%	-2,700	-2,802	-2,859	-3,539	-3,000	-5,887	-4,618	-6,082	-4,122	-4,013	-3,739	-3,861	-3,618	-674	-950	-436	-
Share Based Compensation	-19.6%	152	189	459	306	775	350	662	609	463	1,113	648	434	826	429	565	352	-
Cashflow From Investing	-7.1%	-165	-154	-245	-289	-200	-100	-504	-120	-382	-432	-1,532	-262	-94.99	-12.00	-7.80	-5.20	-
Cashflow From Financing	-	3,568	-	-	7,355	-	-	-	-	-	-1,174	25,366	-25.00	20,369	1,823	1,265	80.00	-

VVOS Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue
Total revenue	$ 13,801	$ 16,024
Cost of sales (exclusive of depreciation and amortization shown separately below)	5,530	6,005
Gross profit	8,271	10,019
Operating expenses
General and administrative	22,479	29,041
Sales and marketing	2,467	5,340
Depreciation and amortization	621	669
Total operating expenses	25,567	35,050
Operating loss	(17,296)	(25,031)
Non-operating income (expense)
Other expense	(212)	(190)
PPP loan forgiveness		1,287
Excess warrant fair value	(6,453)
Change in fair value of warrant liability, net of issuance costs of $645	10,231
Other income	147	89
Loss before income taxes	(13,583)	(23,845)
Net loss	$ (13,583)	$ (23,845)
Net loss per share (basic)	$ (11.14)	$ (25.90)
Net loss per share (diluted)	$ (11.14)	$ (25.90)
Weighted average number of shares of Common Stock outstanding (basic)	1,219,381	920,592
Weighted average number of shares of Common Stock outstanding (diluted)	1,219,381	920,592
Product [Member]
Revenue
Total revenue	$ 6,270	$ 8,381
Service [Member]
Revenue
Total revenue	$ 7,531	$ 7,643

VVOS Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 1,643	$ 3,519
Accounts receivable, net of allowance of $250 and $712, respectively	202	457
Prepaid expenses and other current assets	616	1,448
Total current assets	2,461	5,424
Long-term assets
Goodwill	2,843	2,843
Property and equipment, net	3,314	3,082
Operating lease right-of-use asset	1,385	1,695
Intangible assets, net	420	302
Deposits and other	307	374
Total assets	10,730	13,720
Current liabilities
Accounts payable	2,145	1,411
Accrued expenses	2,334	1,912
Current portion of contract liabilities	2,138	2,926
Current portion of operating lease liability	474	419
Other current liabilities	198	145
Total current liabilities	7,289	6,813
Long-term liabilities
Contract liabilities, net of current portion	289	112
Employee retention credit liability	1,220
Operating lease liability, net of current portion	1,521	1,994
Total liabilities	10,319	8,919
Commitments and contingencies (Note 12)
Stockholders’ equity
Preferred Stock, $0.0001 par value per share. Authorized 50,000,000 shares; no shares issued and outstanding
Common Stock, $0.0001 par value per share. Authorized 200,000,000 shares; issued and outstanding 1,833,877 shares as of December 31, 2023 and 920,592 shares as December 31, 2022
Additional paid-in capital	93,462	84,269
Accumulated deficit	(93,051)	(79,468)
Total stockholders’ equity	411	4,801
Total liabilities and stockholders’ equity	$ 10,730	$ 13,720

About Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was founded in 2016 and is based in Littleton, Colorado.

CEO	Mr. R. Kirk Huntsman
WEBSITE	https://vivos.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	154

Vivos Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Vivos Therapeutics, Inc.? What does VVOS stand for in stocks?

VVOS is the stock ticker symbol of Vivos Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Vivos Therapeutics, Inc. (VVOS)?

As of Thu Apr 25 2024, market cap of Vivos Therapeutics, Inc. is 6.72 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VVOS stock?

You can check VVOS's fair value in chart for subscribers.

What is the fair value of VVOS stock?

You can check VVOS's fair value in chart for subscribers. The fair value of Vivos Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Vivos Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VVOS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Vivos Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether VVOS is over valued or under valued. Whether Vivos Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Vivos Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VVOS.

What is Vivos Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 25 2024, VVOS's PE ratio (Price to Earnings) is -0.49 and Price to Sales (PS) ratio is 0.49. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VVOS PE ratio will change depending on the future growth rate expectations of investors.